NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Cell Free Systems Conference 2019 – Cell-Free Protein Synthesis Scale-Up and GMP Production of Protein Biotherapeutics for Clinical Trials – Poster
Cell Free Systems Conference 2019 - Poster Please click the link to enlarge image, Cell Free Systems Conference 2019
Cell Free Systems Conference 2019 – Antibody Reduction Mitigation during Harvest from Cell-Free Protein Synthesis – Poster
Cell Free Systems Conference 2019 - Poster Antibody Reduction Mitigation during Harvest from Cell-Free Protein Synthesis. Please click the link to enlarge image, Cell Free Systems Conference 2019 Poster
Sutro Biopharma to Participate in the 31st Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro’s CEO, Bill Newell was Live Today on TD Ameritrade, The Watch List
Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments
STRO-002 Initial Safety Data from an Ongoing Phase 1 Trial in Ovarian and Endometrial Cancers presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 29, 2019 STRO-001 Phase 1 Clinical Trial and Dose Escalation Ongoing in...
American Society of Hematology Conference 2019 – STRO-001 – Abstract
Preliminary Results of a Phase 1 Dose Escalation Study of The First-In-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, In Patients With Advanced B-Cell Malignancies. Nirav N. Shah, Amrita Y. Krishnan, Nina D. Shah, John M. Burke, Jason M. Melear, Alexander I....
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – PowerPoint Presentation
To download, Click Here
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster
Antitumor activity of STRO-002, a novel anti-folate receptor -⍺ (FolR⍺) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC) Please Click the Link, AACR...
Sutro Biopharma to Present at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer - Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer...
